Enanta Pharmaceuticals (ENTA) Change in Acquisitions & Divestments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Change in Acquisitions & Divestments data on file, last reported at $53.9 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 1.36% year-over-year to $53.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $287.4 million (up 13.07% YoY) and the FY2025 annual result came in at $262.9 million, down 31.45% from the prior year.
• Change in Acquisitions & Divestments retreated to $53.9 million in Q1 2026, from $101.5 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $134.5 million in Q4 2023 to a low of $26.7 million in Q1 2022.
• A 5-year average of $73.5 million and a median of $72.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 210.73% — and 2024, when it slumped 76.51%.
• Tracing ENTA's Change in Acquisitions & Divestments over 5 years: stood at $104.1 million in 2022, then climbed by 29.22% to $134.5 million in 2023, then plunged by 42.28% to $77.6 million in 2024, then jumped by 30.68% to $101.5 million in 2025, then tumbled by 46.87% to $53.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $53.9 million (Q1 2026), $101.5 million (Q4 2025), and $72.4 million (Q3 2025), per Business Quant data.